Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.

Hedayati SS, Gregg LP, Carmody T, Jain N, Toups M, Rush AJ, Toto RD, Trivedi MH.

JAMA. 2017 Nov 21;318(19):1876-1890. doi: 10.1001/jama.2017.17131.

2.

Abrogated Freud-1/Cc2d1a Repression of 5-HT1A Autoreceptors Induces Fluoxetine-Resistant Anxiety/Depression-Like Behavior.

Vahid-Ansari F, Daigle M, Manzini MC, Tanaka KF, Hen R, Geddes SD, Béïque JC, James J, Merali Z, Albert PR.

J Neurosci. 2017 Dec 6;37(49):11967-11978. doi: 10.1523/JNEUROSCI.1668-17.2017. Epub 2017 Nov 3.

3.

A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.

Richards C, Iosifescu DV, Mago R, Sarkis E, Reynolds J, Geibel B, Dauphin M.

J Psychopharmacol. 2017 Sep;31(9):1190-1203. doi: 10.1177/0269881117722998. Epub 2017 Aug 31.

4.

Backing into the future: pharmacological approaches to the management of resistant depression.

Cowen PJ.

Psychol Med. 2017 Nov;47(15):2569-2577. doi: 10.1017/S003329171700068X. Epub 2017 Aug 25.

5.

Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.

Jha MK, Minhajuddin A, Gadad BS, Greer TL, Mayes TL, Trivedi MH.

Brain Behav Immun. 2017 Nov;66:103-110. doi: 10.1016/j.bbi.2017.07.005. Epub 2017 Jul 8.

PMID:
28698115
6.

How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial.

Adli M, Wiethoff K, Baghai TC, Fisher R, Seemüller F, Laakmann G, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller HJ, Kronmüller KT, Smolka MN, Schlattmann P, Berger M, Ricken R, Stamm TJ, Heinz A, Bauer M.

Int J Neuropsychopharmacol. 2017 Sep 1;20(9):721-730. doi: 10.1093/ijnp/pyx043.

7.

Therapeutic Effects of Phytochemicals and Medicinal Herbs on Depression.

Lee G, Bae H.

Biomed Res Int. 2017;2017:6596241. doi: 10.1155/2017/6596241. Epub 2017 Apr 19. Review.

8.

What Is New in Rome IV.

Schmulson MJ, Drossman DA.

J Neurogastroenterol Motil. 2017 Apr 30;23(2):151-163. doi: 10.5056/jnm16214. Review.

10.

The Impact of Residual Symptoms in Major Depression.

Israel JA.

Pharmaceuticals (Basel). 2010 Aug 3;3(8):2426-2440. Review.

11.

The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments.

Machado-Vieira R, Baumann J, Wheeler-Castillo C, Latov D, Henter ID, Salvadore G, Zarate CA.

Pharmaceuticals (Basel). 2010 Jan 6;3(1):19-41. Review.

12.

Exercise is medicine for patients with major depressive disorders: but only if the "pill" is taken!

Gerber M, Holsboer-Trachsler E, Pühse U, Brand S.

Neuropsychiatr Dis Treat. 2016 Aug 5;12:1977-81. doi: 10.2147/NDT.S110656. eCollection 2016.

13.

Unilateral and bilateral MRI-targeted repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled study.

Blumberger DM, Maller JJ, Thomson L, Mulsant BH, Rajji TK, Maher M, Brown PE, Downar J, Vila-Rodriguez F, Fitzgerald PB, Daskalakis ZJ.

J Psychiatry Neurosci. 2016 Jun;41(4):E58-66.

14.

Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant.

Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK.

Ther Adv Psychopharmacol. 2016 Apr;6(2):99-144. doi: 10.1177/2045125316629071. Epub 2016 Feb 18. Review.

15.

Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data.

Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D, Haffen E, Alonzo A, Loo CK.

Br J Psychiatry. 2016 Jun;208(6):522-31. doi: 10.1192/bjp.bp.115.164715. Epub 2016 Apr 7. Review.

16.

A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression.

Eisendrath SJ, Gillung E, Delucchi KL, Segal ZV, Nelson JC, McInnes LA, Mathalon DH, Feldman MD.

Psychother Psychosom. 2016;85(2):99-110. doi: 10.1159/000442260. Epub 2016 Jan 26.

17.

Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study.

Shinto L, Marracci G, Mohr DC, Bumgarner L, Murchison C, Senders A, Bourdette D.

PLoS One. 2016 Jan 22;11(1):e0147195. doi: 10.1371/journal.pone.0147195. eCollection 2016.

18.

A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.

Richards EM, Mathews DC, Luckenbaugh DA, Ionescu DF, Machado-Vieira R, Niciu MJ, Duncan WC, Nolan NM, Franco-Chaves JA, Hudzik T, Maciag C, Li S, Cross A, Smith MA, Zarate CA Jr.

Psychopharmacology (Berl). 2016 Mar;233(6):1119-30. doi: 10.1007/s00213-015-4195-4. Epub 2016 Jan 4.

19.

Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion.

Dobek CE, Blumberger DM, Downar J, Daskalakis ZJ, Vila-Rodriguez F.

Neuropsychiatr Dis Treat. 2015 Nov 30;11:2975-87. doi: 10.2147/NDT.S91126. eCollection 2015. Review.

20.

Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral Therapy for End-stage Renal Disease Patients with Depression (ASCEND).

Hedayati SS, Daniel DM, Cohen S, Comstock B, Cukor D, Diaz-Linhart Y, Dember LM, Dubovsky A, Greene T, Grote N, Heagerty P, Katon W, Kimmel PL, Kutner N, Linke L, Quinn D, Rue T, Trivedi MH, Unruh M, Weisbord S, Young BA, Mehrotra R.

Contemp Clin Trials. 2016 Mar;47:1-11. doi: 10.1016/j.cct.2015.11.020. Epub 2015 Nov 24.

Supplemental Content

Support Center